MIC — Competitive Intelligence Brief

MIC (MIC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: β-lactam antibiotic. Area: Infectious disease.

marketed β-lactam antibiotic bacterial cell wall Infectious disease Biologic

Target snapshot

MIC (MIC) — TolerogenixX GmbH. MIC is a broad-spectrum antibiotic that inhibits cell wall synthesis by binding to the bacterial cell wall.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MIC TARGET	MIC	TolerogenixX GmbH	marketed	β-lactam antibiotic	bacterial cell wall
Maxipime	Cefepime Hydrochloride	Baxter	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	marketed	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Piperacillin And Tazobactam	Piperacillin Sodium	Pfizer	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Bacterial cell wall; beta-lactamase enzyme	1981-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	Cefazolin Sodium	GSK	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1973-01-01
Administration of Metronidazole plus Amoxicillin	Administration of Metronidazole plus Amoxicillin	University of Chile	marketed	Antibiotic combination	Bacterial DNA (metronidazole); bacterial cell wall/penicillin-binding proteins (amoxicillin)
anti-pseudomonal penicillin	anti-pseudomonal penicillin	Vanderbilt University Medical Center	marketed	Beta-lactam antibiotic (anti-pseudomonal penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (β-lactam antibiotic class)

1. TolerogenixX GmbH · 1 drug in this class